<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-88828" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bivalirudin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Berlioz </surname>
            <given-names>Beric E.</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sanghavi</surname>
            <given-names>Devang K.</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Beric Berlioz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Devang Sanghavi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-88828.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Bivalirudin, a direct thrombin inhibitor, plays a crucial role in the management and treatment of patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction. This comprehensive activity delves into the nuanced aspects of bivalirudin therapy, shedding light on its indications, action, and contraindications. Beyond bivalirudin's established role in PCI, this session explores the broader applications of bivalirudin in thromboembolic disease, cardiopulmonary bypass, and extracorporeal membrane oxygenation. Participants will gain an in-depth understanding of the drug's mechanism of action, adverse event profile, off-label uses, dosing, monitoring parameters, contraindications, and potential drug interactions, empowering them to navigate the complexities of managing patients undergoing PCI and other related conditions. This educational initiative equips healthcare professionals with the&#x000a0;competency to manage diverse aspects of bivalirudin therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Screen patients for potential contraindications or increased bleeding risk factors that may affect the selection and dosing of bivalirudin as an anticoagulant during PCI.</p></list-item><list-item><p>Differentiate the pharmacological properties, mechanism of action, and safety profile of bivalirudin from other anticoagulant agents used in PCI, including unfractionated heparin or low molecular weight heparin.</p></list-item><list-item><p>Select the most appropriate anticoagulant strategy, including the decision to use bivalirudin as a monotherapy or in combination with other antithrombotic agents, based on individual patient factors and the clinical scenario.</p></list-item><list-item><p>Determine strategies&#x000a0;with interventional cardiologists, anesthesiologists, and other healthcare team members to ensure coordinated care, appropriate dosing, and monitoring of bivalirudin during PCI procedures.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=88828&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=88828">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-88828.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Bivalirudin is a direct thrombin inhibitor (DTI) with specific actions indicated for intravenous (IV) anticoagulation in patients with acute myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), and thrombosis in patients with a history of heparin-induced thrombocytopenia (HIT).<xref ref-type="bibr" rid="article-88828.r1">[1]</xref><xref ref-type="bibr" rid="article-88828.r2">[2]</xref><bold>&#x000a0;</bold></p>
        <p>More recently, bivalirudin has been explored and utilized off-label in patients undergoing cardiopulmonary bypass and extracorporeal membrane oxygenation (ECMO) and for deep venous thrombosis prophylaxis.<xref ref-type="bibr" rid="article-88828.r3">[3]</xref><xref ref-type="bibr" rid="article-88828.r4">[4]</xref><xref ref-type="bibr" rid="article-88828.r5">[5]</xref></p>
        <p>
<bold>FDA Approved Indication</bold>
</p>
        <p><bold>Percutaneous Coronary Intervention (PCI):</bold> Bivalirudin is indicated as an anticoagulant in patients undergoing PCI, including those with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS). The use is endorsed by the ACC/AHA/SCAI (The American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography &#x00026; Interventions) guidelines.<xref ref-type="bibr" rid="article-88828.r6">[6]</xref>&#x000a0;</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Heparin-induced thrombocytopenia&#x000a0;<xref ref-type="bibr" rid="article-88828.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Acute myocardial infarction, an adjunct to thrombolytic therapy&#x000a0;<xref ref-type="bibr" rid="article-88828.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Deep venous thrombosis&#x000a0;<xref ref-type="bibr" rid="article-88828.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Peripheral arterial bypass, thromboembolic disorder (prophylaxis)</p>
          </list-item>
          <list-item>
            <p>Extracorporeal membrane oxygenation (ECMO)&#x000a0;<xref ref-type="bibr" rid="article-88828.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Thromboembolic disorder (prophylaxis), unstable angina&#x000a0;<xref ref-type="bibr" rid="article-88828.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Venous thromboembolism&#x000a0;<xref ref-type="bibr" rid="article-88828.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>The BRIGHT 4 trial revealed that in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) primarily via radial artery access, the use of bivalirudin along with a high-dose infusion for 2&#x000a0;to 4 hours after PCI significantly reduced the composite rate of all-cause mortality or major bleeding at 30 days when compared to heparin monotherapy.<xref ref-type="bibr" rid="article-88828.r12">[12]</xref></p>
      </sec>
      <sec id="article-88828.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Bivalirudin is an inhibitor of thrombin, a factor within the coagulation cascade&#x000a0;essential to thrombus formation. Thrombin serves to cleave fibrinogen into fibrin. Fibrin monomers then convert factor XIII to factor XIIIa, allowing for the stabilization of the thrombus. Additionally, fibrin activates factor V and factor VIII, further promoting thrombin and platelet activation.<xref ref-type="bibr" rid="article-88828.r13">[13]</xref>&#x000a0;&#x000a0;&#x000a0;</p>
        <p>Bivalirudin specifically inhibits thrombin by binding to the catalytic site and the anion-binding exosite of thrombin within the thrombi and the circulation. This action contrasts with glycosaminoglycan anticoagulants, including unfractionated heparin and low molecular weight heparin. Heparin's action indirectly inhibits thrombin by serving as an enzyme that catalyzes anti-thrombin, a serine protease inhibitor that forms a covalent bond with thrombin.<xref ref-type="bibr" rid="article-88828.r14">[14]</xref>&#x000a0;This mechanism offers potential advantages, including a more predictable pharmacologic response. Additionally, bivalirudin does not bind to platelet factor 4 and thus does not share cross-reactivity with antibodies in patients with a history of HIT.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Following intravenous administration in patients with PCI, bivalirudin exhibits linear pharmacokinetics. The intravenous administration of bivalirudin results in an immediate anticoagulant effect, reaching a maximum serum concentration after 15&#x000a0;to 20 minutes. The mean bivalirudin concentration reaches 12.3 &#x000b1; 1.7 mcg/mL after an IV bolus in a dose of 1 mg/kg and a 4-hour infusion of 2.5 mg/kg/h. Coagulation times typically return to baseline levels approximately&#x000a0;1 hour after discontinuing bivalirudin.<xref ref-type="bibr" rid="article-88828.r15">[15]</xref><xref ref-type="bibr" rid="article-88828.r16">[16]</xref></p>
        <p><bold>Distribution:</bold> Bivalirudin exhibits a unique feature as it does not bind to&#x000a0;RBCs or other plasma proteins apart from thrombin.</p>
        <p><bold>Metabolism:</bold> The primary mechanism of bio-inactivation of bivalirudin is through proteolytic cleavage.<xref ref-type="bibr" rid="article-88828.r17">[17]</xref></p>
        <p><bold>Elimination:</bold> The elimination half-life of bivalirudin in patients undergoing PCI with normal renal function is 25 minutes. The total body clearance of bivalirudin is 3.4 mL/min/kg. Bivalirudin is primarily excreted renally. The fraction&#x000a0;eliminated unchanged by the kidney is approximately 20%.<xref ref-type="bibr" rid="article-88828.r18">[18]</xref>&#x000a0;</p>
        <p>Bivalirudin demonstrates similar total body clearance in PCI patients with mild renal impairment. The half-life of bivalirudin in patients with normal renal function is 25 minutes. In moderate and severe renal impairment, clearance is reduced by 21%, with corresponding half-lives of 34 and 57 minutes, respectively. In dialysis patients, clearance is diminished by 70% with a half-life of 3.5 hours.</p>
      </sec>
      <sec id="article-88828.s4" sec-type="Administration">
        <title>Administration</title>
        <p><bold>Dosage Forms:&#x000a0;</bold>Bivalirudin is available&#x000a0;for intravenous solution either as a lyophilized powder for suspension or as a solution for injection and ready-to-use (RTU) injection.</p>
        <p>
<bold>Strength</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bivalirudin is available as a 250 mg powder for reconstitution with 5 mL of sterile water or ready for injection as a 5 mg/mL solution.</p>
          </list-item>
          <list-item>
            <p>Bivalirudin (RTU) injection is available at a concentration of 250 mg/50 mL.</p>
          </list-item>
        </list>
        <p>
<bold>Preparation and Administration Instructions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>To reconstitute each 250 mg vial of bivalirudin, add 5 mL of sterile water. To dissolve the constituents, gently stir the mixture.</p>
          </list-item>
          <list-item>
            <p>Withdraw and discard 5 mL from a 50 mL infusion bag containing 5% dextrose in water (D5W) or normal saline.</p>
          </list-item>
          <list-item>
            <p>The reconstituted vial's contents should be added to an infusion bag containing either 0.9% sodium chloride for injection or 5% dextrose in water to provide a final concentration of 5 mg/mL. Adjust the dosage&#x000a0;based on the body weight of the patient.</p>
          </list-item>
        </list>
        <p>
<bold>Administration</bold>
</p>
        <p><bold>Percutaneous Coronary Intervention:</bold>&#x000a0;According to ACC/AHA/SCAI 2021 guidelines,&#x000a0;bivalirudin should be used as a replacement for unfractionated heparin in patients with heparin-induced thrombocytopenia undergoing&#x000a0;PCI to&#x000a0;avoid&#x000a0;thrombotic complications. An initial intravenous dose of 0.75 mg/kg of bivalirudin is recommended, followed&#x000a0;instantaneously by a 1.75 mg/kg/h maintenance infusion for the length of the procedure.</p>
        <p>Assess the activated&#x000a0;clotting time (ACT)&#x000a0;5 minutes after the bolus dosage is given to see if a subsequent&#x000a0;bolus of 0.3 mg/kg is necessary.&#x000a0;If a patient has ST-segment elevation MI (STEMI),&#x000a0;consider&#x000a0;extending the&#x000a0;duration of the infusion at 1.75 mg/kg/h up to 4 hours post-procedure to reduce the risk of in-stent thrombosis. At the physician's discretion, the infusion may continue for up to&#x000a0;4 hours after the intervention. Caution is necessary; watch closely for signs of bleeding, as mentioned in the adverse reactions and toxicity section.<xref ref-type="bibr" rid="article-88828.r19">[19]</xref></p>
        <p><bold>Heparin-induced thrombocytopenia (Off-Label Use)</bold>: According to the American Society of Hematology guidelines, the IV infusion is given at 0.15 mg/kg/h. The dose is adjusted to achieve&#x000a0;APTT 1.5&#x000a0;to 2.5 times from baseline.<xref ref-type="bibr" rid="article-88828.r7">[7]</xref></p>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p><bold>Renal impairment: </bold>No dose adjustment is required in bolus administration; however, maintenance dose adjustment is needed based on creatinine clearance (CrCl) calculated by the Cockcroft-gault equation.&#x000a0;For patients with a CrCl&#x000a0; &#x0003c;30 mL/min, reducing the maintenance dose to 1 mg/kg/h is recommended. The infusion rate should be further decreased to 0.25 mg/kg/h for patients with ESRD undergoing hemodialysis.</p>
        <p><bold>Hepatic impairment: </bold>No dose adjustment information is provided in FDA-approved manufacturer labeling. However, dose reduction may be appropriate in moderate to severe hepatic dysfunction.<xref ref-type="bibr" rid="article-88828.r7">[7]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>The European Society of Cardiology recommends against using bivalirudin during pregnancy.<xref ref-type="bibr" rid="article-88828.r20">[20]</xref>&#x000a0;According to the ACOG (American College of Obstetricians and Gynecologists),&#x000a0;heparin&#x000a0;and LMWH&#x000a0;are the preferred choices for anticoagulation during pregnancy.<xref ref-type="bibr" rid="article-88828.r21">[21]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>No data are currently available regarding the use of bivalirudin during breastfeeding, including its presence in human milk or its impact on the breastfed&#x000a0;infant.&#x000a0;Therefore, caution is advised, and alternative anticoagulants should be considered.<xref ref-type="bibr" rid="article-88828.r22">[22]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>Bivalirudin is not FDA-approved for pediatric use.&#x000a0;Off-label use&#x000a0;has been described.&#x000a0;In a study of pediatric patients undergoing percutaneous intravascular procedures for congenital heart disease, bivalirudin showed a predictable pharmacokinetic/pharmacodynamic response similar to that in adults. Activated clotting time showed a correlation with bivalirudin plasma concentrations. Study findings&#x000a0;indicate that bivalirudin is&#x000a0;a safe and effective anticoagulant in pediatric patients undergoing percutaneous intravascular procedures.<xref ref-type="bibr" rid="article-88828.r23">[23]</xref>&#x000a0;</p>
        <p>A&#x000a0;retrospective&#x000a0;study included 424 patients undergoing ECMO support, both adults and pediatric patients. Among the pediatric patients, 24 received bivalirudin and demonstrated a significant reduction in the composite transfusion requirement within 24 hours with an odds ratio of 0.28 (p = 0.02). These findings indicate the benefits of bivalirudin as an anticoagulant in pediatric ECMO patients.&#x000a0;Additional pivotal trials are needed to validate these findings.<xref ref-type="bibr" rid="article-88828.r24">[24]</xref></p>
        <p><bold>Older&#x000a0;Patients:</bold> Older patients&#x000a0;have more significant bleeding risks associated with bivalirudin. Use with caution.</p>
      </sec>
      <sec id="article-88828.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>The most common adverse effects include hypotension, backache, and nausea.</p>
          </list-item>
          <list-item>
            <p>Major bleeding, cardiogenic shock, cardiac tamponade, and stroke are potential complications associated with using bivalirudin.<xref ref-type="bibr" rid="article-88828.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Diffuse alveolar hemorrhage has been described as a complication of bivalirudin therapy.<xref ref-type="bibr" rid="article-88828.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>The use of bivalirudin in gamma brachytherapy has been linked to an elevated risk of&#x000a0;thrombosis.<xref ref-type="bibr" rid="article-88828.r27">[27]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The risk of bleeding increases with bivalirudin and concomitant use of warfarin, heparin, thrombolytics, or glycoprotein IIb/IIIa inhibitors.<xref ref-type="bibr" rid="article-88828.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Concomitant use of bivalirudin with apixaban, rivaroxaban,&#x000a0;mifepristone, and dabigatran should be avoided due to the increased risk of bleeding.<xref ref-type="bibr" rid="article-88828.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>IV incompatibilities exist between bivalirudin and the following drugs:
<list list-type="bullet"><list-item><p>Alteplase</p></list-item><list-item><p>Amiodarone</p></list-item><list-item><p>Amphotericin B</p></list-item><list-item><p>Chlorpromazine</p></list-item><list-item><p>Dobutamine</p></list-item><list-item><p>Prochlorperazine</p></list-item><list-item><p>Reteplase</p></list-item><list-item><p>Streptokinase</p></list-item><list-item><p>Vancomycin</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-88828.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications are active major bleeding and hypersensitivity to bivalirudin or its components.<xref ref-type="bibr" rid="article-88828.r30">[30]</xref></p>
      </sec>
      <sec id="article-88828.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Key facts to keep in mind regarding monitoring are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>To&#x000a0;monitor the safety and&#x000a0;effectiveness of bivalirudin, measuring activated clotting time (ACT) 5 minutes&#x000a0;following the initial bolus dose is&#x000a0;recommended.<xref ref-type="bibr" rid="article-88828.r19">[19]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Activated partial thromboplastin time (aPTT) (1.5&#x000a0;to 2.5 times the patient&#x02019;s baseline value)&#x000a0;<xref ref-type="bibr" rid="article-88828.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p>Additional monitoring parameters include assessment of signs and symptoms of bleeding, especially in&#x000a0;patients with increased risk of bleeding or in decreased hematocrit or blood pressure, indicating&#x000a0;hemorrhage and myocardial ischemia in patients after at least 24 hours of primary percutaneous&#x000a0;intervention.</p>
          </list-item>
          <list-item>
            <p>ECMO: ISTH (The International Society on Thrombosis and Haemostasis) guidelines recommend monitoring of bivalirudin using aPTT, chromogenic diluted thrombin time (TT), and anti-IIa.<xref ref-type="bibr" rid="article-88828.r32">[32]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-88828.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The toxic effects related to bivalirudin administration primarily pertain to bleeding. No minimum toxic dose is listed; complications can occur at therapeutic doses. In a study by Gleason et al, the no-observed-adverse-effect level (NOAEL), administered to rats intravenously over 24 hours, was 2000 mg/kg/24 h.<xref ref-type="bibr" rid="article-88828.r33">[33]</xref>&#x000a0;Bivalirudin has been used in the pediatric and infant populations, but there is not enough data to recommend dosing adjustments in pediatric patients.<xref ref-type="bibr" rid="article-88828.r34">[34]</xref><xref ref-type="bibr" rid="article-88828.r35">[35]</xref></p>
        <p>Approximately 1.4% to 3.8% of patients will develop significant hemorrhage. Reports exist of intracranial bleeding, retroperitoneal bleeding, and clinically overt bleeding in patients undergoing PCI to treat unstable angina<bold>.&#x000a0;</bold>This risk increases with the concomitant use of aspirin and streptokinase.<xref ref-type="bibr" rid="article-88828.r36">[36]</xref>&#x000a0;In most patients, the primary bleeding site was at the catheterization site. In the event of bleeding, evaluating the need for anticoagulation and deciding to reduce or discontinue the infusion requires clinical judgment.</p>
        <p>Appropriate monitoring includes a CBC, prothrombin time (PT), aPTT, and international normalized ratio (INR). Note that there may be variable responses with these values. Since bivalirudin excretion is primarily via the kidneys, the patient's renal&#x000a0;function requires monitoring.</p>
        <p>Supportive care is recommended, including a fluid bolus and transfusion of platelets or packed red blood cells in thrombocytopenic/anemic patients. In patients with continued bleeding, fresh frozen plasma, prothrombin complex concentrations, and cryoprecipitate may merit consideration. Note that this comes with an inherent risk of developing thromboembolic events. There is no reversal agent available for bivalirudin.</p>
      </sec>
      <sec id="article-88828.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Bivalirudin has proven to be an effective anticoagulant used by interventional cardiologists during PCI in patients with&#x000a0;acute coronary syndrome.&#x000a0;The drug is also an ideal anticoagulant in patients with a history of HIT and has predictable pharmacologic effects. As&#x000a0;bivalirudin use increases, its applications have broadened to include patients who require anticoagulation on cardiopulmonary bypass, ECMO, and deep venous prophylaxis. Given that patients receiving bivalirudin will be in the hospital setting, overdose is rare. Despite this, a multidisciplinary approach to monitoring such patients is necessary.</p>
        <p>Interprofessional team communication and monitoring and prescribing activity coordination between proceduralists, physicians, pharmacists, and nurses are necessary to ensure optimal patient outcomes. Evaluation begins with the appropriate monitoring of patients, including careful assessment at the bedside. The healthcare team must maintain a high degree of clinical vigilance, as the clinical manifestations of bleeding may be confounded by other comorbidities in patients receiving bivalirudin.&#x000a0;Patients should be monitored for&#x000a0;hypotension, tachycardia, and oozing at IV sites should be sought out,&#x000a0;to check for bleeding. A hematologist consultation is required for heparin-induced thrombocytopenia.<xref ref-type="bibr" rid="article-88828.r7">[7]</xref>&#x000a0;</p>
        <p>Laboratory evaluation and imaging studies may be warranted. As a guideline for therapeutic response, the aPTT is&#x000a0;the most commonly used metric.&#x000a0;Dosing regimens should then be adjusted accordingly by a pharmacist and ordering clinician.&#x000a0;Dosing protocols have been developed for monitoring bivalirudin therapy and are usually specific to the institution. Interprofessional care coordination and communication among clinicians and pharmacists achieve the best patient outcomes with the fewest adverse reactions.&#x000a0;</p>
      </sec>
      <sec id="article-88828.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=88828&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=88828">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/88828/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=88828">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-88828.s11">
        <title>References</title>
        <ref id="article-88828.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lupi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rognoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cavallino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Secco</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Reale</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cossa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rosso</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bongo</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Cortese</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Porto</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Intracoronary vs intravenous bivalirudin bolus in ST-elevation myocardial infarction patients treated with primary angioplasty.</article-title>
            <source>Eur Heart J Acute Cardiovasc Care</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>487</fpage>
            <page-range>487-96</page-range>
            <pub-id pub-id-type="pmid">26163529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koster</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bivalirudin.</article-title>
            <source>Thromb Haemost</source>
            <year>2008</year>
            <month>May</month>
            <volume>99</volume>
            <issue>5</issue>
            <fpage>830</fpage>
            <page-range>830-9</page-range>
            <pub-id pub-id-type="pmid">18449412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janjua</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nussbaum</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lowary</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Babbini</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Bivalirudin as a bridge for anticoagulation in high risk neurosurgical patients with active DVT or high risk of thrombosis.</article-title>
            <source>Neurocrit Care</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>349</fpage>
            <page-range>349-53</page-range>
            <pub-id pub-id-type="pmid">23568093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koster</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dyke</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Aldea</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Smedira</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Aronson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hetzer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Avery</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Spiess</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lincoff</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>83</volume>
            <issue>2</issue>
            <fpage>572</fpage>
            <page-range>572-7</page-range>
            <pub-id pub-id-type="pmid">17257990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berlioz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaseer</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Sanghavi</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Guru</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Bivalirudin resistance in a patient on veno-venous extracorporeal membrane oxygenation with a therapeutic response to argatroban.</article-title>
            <source>BMJ Case Rep</source>
            <year>2020</year>
            <month>Jan</month>
            <day>07</day>
            <volume>13</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">31915185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Writing Committee Members</collab>
              <name>
                <surname>Lawton</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Tamis-Holland</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bangalore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Beckie</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Bischoff</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bittl</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>DiMaio</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Don</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Fremes</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Gaudino</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Goldberger</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Jaswal</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Kurlansky</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mehran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Metkus</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Sellke</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yong</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Zwischenberger</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint&#x000a0;Committee&#x000a0;on&#x000a0;Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>Jan</month>
            <day>18</day>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>197</fpage>
            <page-range>197-215</page-range>
            <pub-id pub-id-type="pmid">34895951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arepally</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Cines</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gruel</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Linkins</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Rodner</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Selleng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Wex</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mustafa</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Santesso</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.</article-title>
            <source>Blood Adv</source>
            <year>2018</year>
            <month>Nov</month>
            <day>27</day>
            <volume>2</volume>
            <issue>22</issue>
            <fpage>3360</fpage>
            <page-range>3360-3392</page-range>
            <pub-id pub-id-type="pmid">30482768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coughlan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kastrati</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bivalirudin in patients with ST-segment elevation myocardial infarction.</article-title>
            <source>Lancet</source>
            <year>2022</year>
            <month>Nov</month>
            <day>26</day>
            <volume>400</volume>
            <issue>10366</issue>
            <fpage>1822</fpage>
            <page-range>1822-1823</page-range>
            <pub-id pub-id-type="pmid">36351460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Netley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Greenlee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hart</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Todt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Statz</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Bivalirudin Anticoagulation Dosing Protocol for Extracorporeal Membrane Oxygenation: A Retrospective Review.</article-title>
            <source>J Extra Corpor Technol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>161</fpage>
            <page-range>161-166</page-range>
            <pub-id pub-id-type="pmid">30250342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carswell</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Plosker</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Bivalirudin: a review of its potential place in the management of acute coronary syndromes.</article-title>
            <source>Drugs</source>
            <year>2002</year>
            <volume>62</volume>
            <issue>5</issue>
            <fpage>841</fpage>
            <page-range>841-70</page-range>
            <pub-id pub-id-type="pmid">11929334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Regling</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Callaghan</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Rajpurkar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bivalirudin during thrombolysis with catheter-directed tPA in a heparin-refractory patient: A case report.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>e28094</fpage>
            <pub-id pub-id-type="pmid">31749252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.</article-title>
            <source>Lancet</source>
            <year>2022</year>
            <month>Nov</month>
            <day>26</day>
            <volume>400</volume>
            <issue>10366</issue>
            <fpage>1847</fpage>
            <page-range>1847-1857</page-range>
            <pub-id pub-id-type="pmid">36351459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weisel</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Litvinov</surname>
                <given-names>RI</given-names>
              </name>
            </person-group>
            <article-title>Fibrin Formation, Structure and Properties.</article-title>
            <source>Subcell Biochem</source>
            <year>2017</year>
            <volume>82</volume>
            <fpage>405</fpage>
            <page-range>405-456</page-range>
            <pub-id pub-id-type="pmid">28101869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weitz</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Middeldorp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Geerts</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Heit</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Thrombophilia and new anticoagulant drugs.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2004</year>
            <fpage>424</fpage>
            <page-range>424-38</page-range>
            <pub-id pub-id-type="pmid">15561696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics, pharmacodynamics, tolerability and safety of single doses of bivalirudin in healthy chinese subjects.</article-title>
            <source>Biol Pharm Bull</source>
            <year>2011</year>
            <volume>34</volume>
            <issue>12</issue>
            <fpage>1841</fpage>
            <page-range>1841-8</page-range>
            <pub-id pub-id-type="pmid">22130240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ko&#x00142;towski</surname>
                <given-names>&#x00141;</given-names>
              </name>
              <name>
                <surname>Legutko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Filipiak</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dziewierz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bartu&#x0015b;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Buszman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Buszman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cie&#x00107;wierz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>D&#x00105;browski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dobrzycki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gil</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gor&#x00105;cy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grygier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jaguszewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kochman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kubica</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuliczkowki</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lodzi&#x00144;ski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ocha&#x00142;a</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reczuch</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Witkowski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wojakowski</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>W&#x000f3;jcik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dudek</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society.</article-title>
            <source>Cardiol J</source>
            <year>2019</year>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">30882184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van De Car</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Bivalirudin: a review of the pharmacology and clinical application.</article-title>
            <source>Expert Rev Cardiovasc Ther</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>1673</fpage>
            <page-range>1673-81</page-range>
            <pub-id pub-id-type="pmid">21108549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sciulli</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Mauro</surname>
                <given-names>VF</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology and clinical use of bivalirudin.</article-title>
            <source>Ann Pharmacother</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>1028</fpage>
            <page-range>1028-41</page-range>
            <pub-id pub-id-type="pmid">12022907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Writing Committee Members</collab>
              <name>
                <surname>Lawton</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Tamis-Holland</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bangalore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Beckie</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Bischoff</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bittl</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>DiMaio</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Don</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Fremes</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Gaudino</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Goldberger</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Jaswal</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Kurlansky</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mehran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Metkus</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Sellke</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yong</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Zwischenberger</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint&#x000a0;Committee&#x000a0;on&#x000a0;Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>Jan</month>
            <day>18</day>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>e21</fpage>
            <page-range>e21-e129</page-range>
            <pub-id pub-id-type="pmid">34895950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>European Society of Gynecology (ESG)</collab>
              <collab>Association for European Paediatric Cardiology (AEPC)</collab>
              <collab>German Society for Gender Medicine (DGesGM)</collab>
              <name>
                <surname>Regitz-Zagrosek</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Blomstrom Lundqvist</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cifkova</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Foidart</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Gohlke-Baerwolf</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gorenek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Iung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kirby</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maas</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Morais</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nihoyannopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Presbitero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roos-Hesselink</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Schaufelberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seeland</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Torracca</surname>
                <given-names>L</given-names>
              </name>
              <collab>ESC Committee for Practice Guidelines</collab>
            </person-group>
            <article-title>ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).</article-title>
            <source>Eur Heart J</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>32</volume>
            <issue>24</issue>
            <fpage>3147</fpage>
            <page-range>3147-97</page-range>
            <pub-id pub-id-type="pmid">21873418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bates</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Middeldorp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rodger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Guidance for the treatment and prevention of obstetric-associated venous thromboembolism.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>92</fpage>
            <page-range>92-128</page-range>
            <pub-id pub-id-type="pmid">26780741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <chapter-title>Bivalirudin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">29999833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forbes</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Hijazi</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ringewald</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Aquino</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rome</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rhodes</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Moskowitz</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Holzer</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Zamora</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pediatric catheterization laboratory anticoagulation with bivalirudin.</article-title>
            <source>Catheter Cardiovasc Interv</source>
            <year>2011</year>
            <month>Apr</month>
            <day>01</day>
            <volume>77</volume>
            <issue>5</issue>
            <fpage>671</fpage>
            <page-range>671-9</page-range>
            <pub-id pub-id-type="pmid">21433272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seelhammer</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Bohman</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Schulte</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Aganga</surname>
                <given-names>DO</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Bivalirudin Versus Heparin for Maintenance Systemic Anticoagulation During Adult and Pediatric Extracorporeal Membrane Oxygenation.</article-title>
            <source>Crit Care Med</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>49</volume>
            <issue>9</issue>
            <fpage>1481</fpage>
            <page-range>1481-1492</page-range>
            <pub-id pub-id-type="pmid">33870916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Occurrence and Risk Factors of Adverse Drug Reactions in Patients Receiving Bivalirudin as Anticoagulant During Percutaneous Coronary Intervention: A Prospective, Multi-Center, Intensive Monitoring Study.</article-title>
            <source>Front Cardiovasc Med</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>781632</fpage>
            <pub-id pub-id-type="pmid">35573935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Latt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aung</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kyaw</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aung</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Roongsritong</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A Case of Diffuse Alveolar Hemorrhage as a Possible Complication of Bivalirudin Therapy.</article-title>
            <source>Am J Case Rep</source>
            <year>2017</year>
            <month>Oct</month>
            <day>10</day>
            <volume>18</volume>
            <fpage>1081</fpage>
            <page-range>1081-1085</page-range>
            <pub-id pub-id-type="pmid">28993605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuchulakanti</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Satler</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Rha</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Waksman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Bivalirudin-associated intracoronary thrombosis during gamma-brachytherapy and its experimental validation in acute swine model.</article-title>
            <source>Catheter Cardiovasc Interv</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-13</page-range>
            <pub-id pub-id-type="pmid">15170713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caron</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>McKendall</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Bivalirudin in percutaneous coronary intervention.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2003</year>
            <month>Sep</month>
            <day>15</day>
            <volume>60</volume>
            <issue>18</issue>
            <fpage>1841</fpage>
            <page-range>1841-9</page-range>
            <pub-id pub-id-type="pmid">14521034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>RX</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>XW</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>[Analysis of management efficacy in patients with heavy menstrual bleeding associated with antithrombotic therapy].</article-title>
            <source>Zhonghua Fu Chan Ke Za Zhi</source>
            <year>2023</year>
            <month>Apr</month>
            <day>25</day>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>286</fpage>
            <page-range>286-292</page-range>
            <pub-id pub-id-type="pmid">37072297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Showkathali</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Natarajan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review.</article-title>
            <source>Curr Cardiol Rev</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>239</fpage>
            <page-range>239-49</page-range>
            <pub-id pub-id-type="pmid">22935021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>ZC</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Management of Bivalirudin Anticoagulation Therapy for Extracorporeal Membrane Oxygenation in Heparin-Induced Thrombocytopenia: A Case Report and a Systematic Review.</article-title>
            <source>Front Pharmacol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>565013</fpage>
            <pub-id pub-id-type="pmid">33013402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Helms</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frere</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Anticoagulation in adult patients supported with extracorporeal membrane oxygenation: guidance from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis.</article-title>
            <source>J Thromb Haemost</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>373</fpage>
            <page-range>373-396</page-range>
            <pub-id pub-id-type="pmid">36700496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gleason</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Chengelis</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Lindstrom</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>A 24-hour continuous infusion study of bivalirudin in the rat.</article-title>
            <source>Int J Toxicol</source>
            <year>2003</year>
            <season>May-Jun</season>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-206</page-range>
            <pub-id pub-id-type="pmid">12851152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buck</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Bivalirudin as an Alternative to Heparin for Anticoagulation in Infants and Children.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2015</year>
            <season>Nov-Dec</season>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>408</fpage>
            <page-range>408-17</page-range>
            <pub-id pub-id-type="pmid">26766931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagle</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Dager</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Duby</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Kenny</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Pretzlaff</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Bivalirudin in pediatric patients maintained on extracorporeal life support.</article-title>
            <source>Pediatr Crit Care Med</source>
            <year>2013</year>
            <month>May</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>e182</fpage>
            <page-range>e182-8</page-range>
            <pub-id pub-id-type="pmid">23648880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88828.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Aylward</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Adgey</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hillis</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Shalev</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maraganore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Adelman</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.</article-title>
            <source>Circulation</source>
            <year>1997</year>
            <month>Oct</month>
            <day>07</day>
            <volume>96</volume>
            <issue>7</issue>
            <fpage>2155</fpage>
            <page-range>2155-61</page-range>
            <pub-id pub-id-type="pmid">9337184</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
